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Summary
In humans, T cells differentiate in thymus and B cells
develop in bone marrow (BM), but the natural killer
(NK) precursor cell(s) and site(s) of NK development
are unclear. The CD56bright NK subset predominates
in lymph nodes (LN) and produces abundant cytokines
compared to the cytolytic CD56dim NK cell that predomi-
nates in blood. Here, we identify a novel CD34dim
CD45RA(+) hematopoietic precursor cell (HPC) that is
integrin 47bright. CD34dimCD45RA(+)7bright HPCs
constitute <1% of BM CD34(+) HPCs and 6% of blood
CD34(+) HPCs, but >95% of LN CD34(+) HPCs. They
reside in the parafollicular T cell regions of LN with
CD56bright NK cells, and when stimulated by IL-15, IL-2,
or activated LN T cells, they become CD56bright NK
cells. The data identify a new NK precursor and sup-
port a model of human NK development in which BM-
derived CD34dimCD45RA(+)7bright HPCs reside in LN
where endogenous cytokines drive their differentia-
tion to CD56bright NK cells in vivo.
Introduction
Human natural killer (NK) cells are CD3(−)CD14(−)
CD56(+) large granular lymphocytes that can kill in-
fected or transformed cells that fail to express normal
MHC class I molecules, thereby complementing protec-
tion provided by T cells (Colucci et al., 2003). Similar to
other lymphocytes, the total human NK cell population
is heterogeneous, with the CD56bright and CD56dim sub-
sets representing two phenotypically and functionally
distinct subsets (Cooper et al., 2001). CD56bright NK
cells have few cytotoxic granules, and low expression
of the low-affinity Fc receptor CD16 and killer immuno-
globulin-like receptors (KIR), all consistent with poor
cytolytic properties, but are capable of potent activa-*Correspondence: caligiuri-1@medctr.osu.edution-induced cytokine and chemokine production (Coo-
per et al., 2001; Fehniger et al., 2003). By comparison,
CD56dim NK cells have abundant cytolytic granules and
high surface density expression of CD16 and KIR for
potent antibody-dependent and natural cytolytic func-
tion, with little ability to produce immunomodulatory
cytokines. Currently, the developmental relationship
between the CD56bright and CD56dim human NK subsets
is unclear, as is their site(s) of differentiation. While
R90% of NK cells in peripheral blood (PB) are CD56dim,
>90% of NK cells in lymph nodes (LN) are CD56bright
(Cooper et al., 2001; Fehniger et al., 2003). A recent
study by Munz and colleagues showed that the resi-
dent CD56bright NK cells in LN and tonsils could be in-
duced with interleukin (IL)-2 to adopt functional and
phenotypic qualities of PB CD56dim NK cells (Ferlazzo
et al., 2004), suggesting that CD56bright NK cells may
be less mature than CD56dim NK cells in a sequential
scheme of human NK development. Considering these
findings, we hypothesized that LN might be a site of
early human NK development in vivo.
A correlate to this hypothesis is that the human NK
cell precursor would need to reside in LN. Similar to
other leukocyte populations, human NK cells are ulti-
mately derived from CD34(+) hematopoietic precursor
cells (HPCs), yet the precise phenotype of the human
NK precursor cell is unknown (Colucci et al., 2003; Yo-
koyama et al., 2004). Culture of purified human bone
marrow (BM) CD34(+) HPCs in either IL-2 or IL-15 pri-
marily results in the generation of CD56bright NK cells
(Mrozek et al., 1996). Similarly, mouse NK cells can be
generated by in vitro culture of immature BM progeni-
tors in IL-2 or IL-15 (Williams et al., 1997). Both IL-2 and
IL-15 signal in part via a common IL-2/IL-15 receptor
(R) β chain (Waldmann et al., 1998), and IL-2/IL-15Rβ-
deficient mice are severely deficient in mature NK cells
(Suzuki et al., 1997). Indeed, the lineage (Lin)(−)IL-
2Rβ(+) population in mouse BM has clearly been iden-
tified as the committed mouse NK precursor cell
(Rosmaraki et al., 2001); however, IL-2/IL-15Rβ expres-
sion on freshly isolated human CD34(+) HPCs is below
the limits of detection by flow cytometry (Shibuya et al.,
1993; Yu et al., 1998). Therefore, while the human NK
precursor can be defined by its functional ability to dif-
ferentiate into a CD56bright NK cell in response to IL-2
or IL-15, the precise phenotype of this CD34(+) HPC
remains elusive.
Previous work by other laboratories has provided in-
valuable insight into the phenotype of the CD34(+) hu-
man NK precursor by associating surface antigen ex-
pression with NK precursor function. For example,
Miller and colleagues provided early evidence that
coexpression of CD7 on CD34(+) HPCs selectively en-
riches for NK precursors (Miller et al., 1994). In addition,
work by the Chen laboratory demonstrated that the
coexpression of CD10 on BM CD34(+) HPCs identified
the human common lymphoid progenitor (CLP) that in-
cluded the NK precursor (Galy et al., 1995). Despite
these advances, both CD34(+)CD7(−) and CD34(+)
CD10(−) HPC populations also contain some NK pre-
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296Figure 1. Coexpression of CD45RA on
CD34(+) HPCs Identifies the Human NK Pre-
cursor
CD34(+)CD45RA(−) and CD34(+)CD45RA(+)
populations from BM (n = 3) and PB (n = 7)
were sorted and cultured for 2 weeks in 10
pM IL-2, 1 nM IL-2, or 1 nM IL-15. Results
shown are representative. Only CD34(+)
CD45RA(+) cells differentiate into CD56bright
NK cells in IL-2 or IL-15.cursors, as determined by differentiation into CD56bright u
lNK cells following incubation in IL-2 or IL-15 (Canque
et al., 2000; Galy et al., 1995; Miller et al., 1994). Thus, b
Ithe “all-inclusive” human CD34(+) NK precursor cell re-
mains to be identified. T
CHere, we identify a novel subset of CD34dim HPCs
that constitutively expresses CD45RA and high-surface (
cdensity integrin α4β7, with functional evidence for ex-
pression of the heterotrimeric high-affinity (HA) IL-2Rαβγ. s
aThe CD34dimCD45RA(+)β7bright subset of CD34(+) HPCs
is selectively and highly enriched for within human LN c
Nand resides in the T cell-rich regions along with CD56bright
NK cells. The CD34dimCD45RA(+)β7bright subset is unique 3
(in that differentiation into functional CD56bright NK cells
appears to occur exclusively within this CD34(+) HPC c
csubset and can occur in the presence of IL-15 or at con-
centrations of IL-2 that only saturate its HA IL-2R. Further,
we show that activated LN T cells can also promote the F
differentiation of the CD34dimCD45RA(+)β7bright NK pre- o
cursor into a CD56bright NK cell in vitro. The data sup- T
port a model of human NK development in which a BM- f
derived CD34dimCD45RA(+)β7bright NK cell precursor s
population selectively resides in LN where endogenous p
cytokines can drive its differentiation into CD56bright NK k




pHuman NK Precursors Are Enriched
within Peripheral Blood d
bThe CD56bright NK cell is the only resting lymphocyte
population in blood to constitutively express a hetero- c
ntrimeric HA IL-2Rαβγ (Caligiuri et al., 1990; Nagler et al.,
1990). To identify its precursor, we first searched for a C
isubset of CD34(+) HPCs that might also express the HA
IL-2Rαβγ and differentiate into a CD56bright NK cell via u
signaling through this receptor. The HA IL-2Rαβγ isnique in that it can signal following the binding of very
ow concentrations (10 pM or 2.3 U/ml) of IL-2, and this
inding can be completely abrogated with the anti-
L-2Rα monoclonal antibody (mAb) (Queen et al., 1989).
his population was found entirely within the
D45RA(+) subset of CD34(+) HPCs of both BM and PB
Figure 1). We observed identical results in nanomolar
oncentrations of either IL-15 or IL-2 that utilize the
hared IL-2/IL-15Rβγ, but not the IL-2Rα (Waldmann et
l., 1998) (not shown). Importantly, there was a signifi-
ant difference in the absolute numbers of CD56bright
K cells derived from 2 × 104 CD34(+) BM HPCs (537 ±
40, n = 9) versus an equal number of PB CD34(+) HPCs
6831 ± 4329, n = 5) (p = 0.0013), suggesting that PB
ontains a much higher percentage of CD34(+) NK pre-
ursors than BM (see below).
unctional and Phenotypic Characterization
f the CD34(+)-Derived CD56bright NK Cells
he CD56bright NK cells derived under these conditions
rom CD34(+) HPCs were cytotoxic against the NK-sen-
itive K562 cell line (Figure 2A) and capable of cytokine
roduction when costimulated in recombinant mono-
ines (Figure 2B and Table S1; see the Supplemental
ata available with this article online). Similar to PB
D56bright NK cells, these cells could not produce cyto-
ines when only cocultured with K562 targets (not
hown). Figures 2C and 2D provide a representative
henotype of CD34(+)-derived CD56bright NK cells. We
id not observe any consistent phenotypic differences
etween BM or PB CD34(+)-derived CD56bright NK
ells, but a few distinct differences in phenotype were
oted between these cells (Figure 2C) and mature PB
D56bright NK cells (Figure S1). For example, fresh or
n vitro-cultured mature PB CD56bright NK cells display
niform expression of CD94 (bright) and leukocytefunction-associated antigen-1 (LFA-1), whereas most of
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297Figure 2. Functional and Phenotypic Attributes of CD34(+)-Derived CD56bright NK Cells
(A) CD34(+)-derived CD56bright NK cells are cytotoxic against K562 target cells at the indicated effector:target cell ratios. Results are represen-
tative of six experiments.
(B) IFN-γ production by CD34(+)-derived CD56bright NK cells. The dot plots were gated on CD3(−)CD14(−) events.
(C) Surface expression of CD34(+)-derived CD56bright NK cells. The histograms were gated on CD3(−)CD14(−)CD56bright events; shaded regions
represent staining with the specific mAbs as indicated, whereas dotted lines (open regions) represent isotype controls. No consistent differ-
ences in function or phenotype were observed between CD56bright NK cells derived from CD34(+) cells of BM or PB origin.
(D) Representative phenotypic comparison of CD56bright NK cells derived from CD34(+) HPCs following a 2 week culture in IL-2 or IL-15
versus purified mature PB CD56bright NK cells cultured for 2 weeks in IL-2 or IL-15. Comparing Figure 2C and Figure S1 also shows a
difference in NKp44 expression.the CD34(+)-derived CD56bright NK cells lack these anti-
gens (Figure 2D). Given these qualitative differences in
phenotype, the consistent high purities of our CD34
preparations (Figure S2), and the very limited growth
potential of mature PB CD56bright NK cells cultured ex
vivo (Fehniger et al., 2000), the detection of CD56bright
NK cells following prolonged cultures of CD34(+) HPCs
with IL-2 or IL-15 cannot result from contamination by
mature PB CD56bright NK cells. Rather, these data col-
lectively show that the human NK precursor cell that dif-
ferentiates to a CD56bright NK cell in the presence of IL-
15 or IL-2 is found exclusively within CD34(+)CD45RA(+)
HPCs and is more abundant in PB than in BM.
Refinement of the Phenotype of the
CD34(+)CD45RA(+) NK Cell Precursor
Our statistical analyses of NK precursor frequency in
BM and PB noted above suggested that these
CD34(+)CD45(+) NK precursor cells may be traffickingout of the BM to the periphery. We therefore analyzed
surface expression of homing and chemokine re-
ceptors and cell adhesion molecules (CAMs) on PB
CD34(+) HPCs. We observed that all PB CD34(+) cells
express similar levels of α4β1 integrin and PEN5 (not
shown), whereas CD34(+)CD45RA(+) cells display rela-
tively higher levels of LFA-1 compared to CD34(+)
CD45RA(−) HPCs (Figure 3). While PB CD56bright NK cells
express CCR7 and CXCR3 (Cooper et al., 2001; Vitale
et al., 2004), we could not detect the expression of
either of these chemokine receptors on any PB CD34(+)
subset (not shown). Interestingly, we found that among
total PB CD34(+) cells, a unique CD34dimCD45RA(+)
subset expresses very high levels of L-selectin and in-
tegrin α4β7 (represented by integrin β7, Figure 3). Of note,
these cells are distinct from CD34dimCD45RA(+)CD4(+)
IL-3Rαbright pro-DC2 cells (Blom et al., 2000), which are
IL-2Rα(−)c-kit(−)α β dim (unpublished data) and were4 7
depleted from our PB CD34 preparations with an anti-
Immunity
298Figure 3. Phenotypic Analysis of PB CD34(+) HPC Subsets
Dotted lines (open regions) in the histograms represent isotype control staining of total PB CD34(+) cells, shaded regions represent surface
expression on CD34dimCD45RA(+) cells, solid lines (open regions) represent expression on CD34brightCD45RA(+) cells, and dashed lines (open
regions) represent expression on CD34(+)CD45RA(−) cells. Prior to staining for flow cytometry, CD19(+) and CD4(+) cells, including pro-B
(Lassoued et al., 1993) and pro-DC2 (Blom et al., 2000) HPCs, were removed (see the Experimental Procedures). The data shown are represen-
tative of ten donors.CD4 mAb (see the Experimental Procedures). The PB o
sCD34dimCD45RA(+) subset we describe here is strik-
ingly reminiscent of mature PB CD56bright NK cells a
tbased on its expression of CD2, CD7, NKR-P1A, and
c-kit (shaded histograms in Figure 3 and Figure S1) p
a(Cooper et al., 2001). In contrast, the majority of PB
CD34brightCD45RA(+) cells (open regions with solid w
wlines in Figure 3) lack these markers yet express surface
CD10, suggesting that this population may be function- r
cally similar to the CD34(+)CD10(+) CLP previously de-
scribed in adult BM (Galy et al., 1995). In addition, the G
wCD34brightCD45RA(+) subset expresses the early stem
cell marker, AC133, potentially indicating that this sub- f
uset is relatively immature compared to the CD34dim
CD45RA(+) subset that displays no AC133 (Figure 3) t
m(Yin et al., 1997).
Subtle overlaps in phenotype between the two PB I
gCD34(+)CD45RA(+) populations presented an initial
challenge to sort these subsets to high purity. For ex- t
pample, not all the CD34dimCD45RA(+) cells are CD10(−),
and not all the CD34brightCD45RA(+) cells are CD7(−) C
p(Figure 3). Among the surface markers we analyzed, rel-
ative bright expression of integrin β7 best differentiated 2
othe CD34dimCD45RA(+) subset not only from other
CD34(+) subsets, but also from mature CD56bright and o
wCD56dim NK cells, which have absent or low expressionf integrin β7, respectively (Figure S1 and data not
hown). Therefore, we used a combination of mAbs
gainst CD34, CD45RA, and integrin β7 to purify the
wo PB CD34(+)CD45RA(+) subsets and to reduce the
otential for mature NK cell contamination in our sorts,
representative of which is shown in Figure 4. After 2
eeks of culture in 10 pM IL-2 or 1 nM IL-15 or IL-2,
e observed that the CD34dimCD45RA(+)β7bright subset
epeatedly gave rise to CD3(−)CD14(−)CD56bright NK
ells (n = 11) by FACS with excellent purity (Figure 4).
enerally, we observed only w1- to 3-fold expansion
hen the cells were cultured in 10 pM IL-2, and w15-
old expansion when cultured in 1 nM IL-2 or IL-15 (Fig-
re S3). However, there was much greater expansion of
hese cells when cultured on the AFT024 fetal liver stro-
al cell line (Miller et al., 1999) in the presence of 1 nM
L-2 and 100 ng/ml flt3 ligand (FL), 100 ng/ml c-kit li-
and (KL), and 10 ng/ml IL-7 (Figure S3), indicating that
hese cells are highly proliferative when cultured in the
resence of excess cytokines and cellular support. The
D56bright NK cells derived on the AFT024 line dis-
layed the same phenotype as that shown in Figures
C and 2D (not shown). In stark contrast to the results
btained from the CD34dimCD45RA(+)β7bright subset, most
f the CD34brightCD45RA(+)β7dim/neg cells died in culture
ith only IL-2 or IL-15 (not shown), and none of the
A CD34(+) NK Precursor in Human Lymph Nodes
299Figure 4. The PB CD34dimCD45RA(+)β7bright
Subset Uniquely Differentiates into CD56bright
NK Cells in IL-2 or IL-15
PB CD34brightCD45RA(+)β7dim/neg and CD34dim
CD45RA(+)β7bright cells were sorted and sub-
sequently cultured for 2 weeks in 10 pM IL-2
or 1 nM IL-2 or IL-15, followed by FACS analy-
sis to assess for CD3(−)CD14(−)CD56bright
NK cell development. The results are repre-
sentative of 11 donors.live cells had the CD3(−)CD14(−)CD56bright phenotype
(Figure 4). Based on these results and those from Fig-
ure 1, we conclude that the CD56bright NK precursor
population is contained exclusively within the CD34dim
CD45RA(+)β7bright PB subset.
CD34dimCD45RA(+)7bright Cells Reside in Human LN
In contrast to PB, whereR90% of NK cells are CD56dim,
>90% of NK cells in human LN are CD56bright and are
located in the parafollicular T cell-rich regions (Fehniger
et al., 2003). One potential model predicts that
CD56bright NK cells develop in the BM and traffic to LN,
where they participate in the immune response through
release of IFN-γ and other cytokines (Colucci et al.,
2003; Cooper et al., 2004; Fehniger et al., 2003; Fer-
lazzo et al., 2004; Vitale et al., 2004). An alternative
model is that BM-derived NK precursors first traffic
through PB to LN, where they can differentiate into
CD56bright NK cells in response to endogenous cytokines.
Indeed, consistent with the significantly greater number
of CD56bright NK cells derived from PB versus BM
CD34(+) HPCs noted above, <1% of BM CD34(+) HPCs
display the phenotype of the CD34dimCD45RA(+)β7bright
population shown in Figure 3 (n = 5), compared to w6%
of PB CD34(+) HPCs (n = 20). These data support the
possibility that at least a subset of NK precursors isdestined for the periphery. Further, in addition to integ-
rin α4β7, our data also show that the PB CD34dim
CD45RA(+)β7bright subset displays very high surface
density expression of LFA-1 and L-selectin (Figure 3),
all three of which can facilitate the extravasation of leu-
kocytes across LN high endothelial venules (von An-
drian and Mempel, 2003).
To test the hypothesis that CD34dimCD45RA(+)β7bright
cells reside in LN, phenotypic analyses of CD34(+)-
enriched single-cell LN suspensions from eight indivi-
dual donors were performed. In striking contrast to PB,
nearly the entire CD34(+) population discovered within
human LN was CD34dimCD45RA(+)β7bright (Figures 5A
and 5B). Thus, while the CD34dimCD45RA(+)β7bright sub-
set represents only w6% of all PB CD34(+) HPCs, this
subset represents >95% of all LN CD34(+) HPCs (n =
8). This natural and nearly exclusive enrichment for the
CD34dimCD45RA(+)β7bright subset of CD34(+) HPCs in
LN eliminates PB contamination as the source of these
cells. Further, PB CD34dimCD45RA(+)β7bright cells ex-
press high levels of surface L-selectin, while the LN
CD34dimCD45RA(+)β7bright cells had lower or absent ex-
pression (compare Figure 3, bottom right panel to Fig-
ure 5B). This suggests that L-selectin may be involved
in the extravasation of PB CD34dimCD45RA(+)β7bright
cells into LN and may subsequently downregulate upon
Immunity
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(A) Comparative flow cytometric analysis of CD34(+) HPC subsets in PB and LN following enrichment for CD34(+) cells in each tissue. In
contrast to PB, LN CD34(+) cells are almost exclusively CD34dimCD45RA(+)β7bright.
(B) Surface antigen expression of enriched LN CD34(+) cells as determined by flow cytometric analysis. The CD34dimCD45RA(+)β7bright subset
in LN is strikingly similar to the subset in PB, except for the former’s low or absent L-selectin expression (compare with bottom right panel
in Figure 3).
(C) In situ RT-PCR for CD34 mRNA on human LN sections. The power of these images is 1000×. Control primers used in the left panel were
specific for the human papilloma virus (HPV) p16 gene (Nuovo et al., 1999). The red arrow in the right panel indicates a representative
LN CD34(+) cell detected by this method. Note the uniform cytoplasmic signal coming from this cell, which is indicative of cytoplasmic
CD34 mRNA.
(D) CD34(+) cells reside within the parafollicular T cell-rich regions of LN. Shown in the right panel is the same LN section depicted on the
right in (C), but at a lower power (200×). The red arrow in both images indicates the location of the CD34(+) cell detected by in situ RT-PCR.
On the left is a serial section from the same region of the LN stained with an anti-CD3 mAb. Cells with brown staining are CD3(+). GC,
germinal center; PF, parafollicular region.entrance (von Andrian and Mempel, 2003). As shown in C
tFigure 5C, we were able to detect CD34(+) cells within
LN tissue sections by using in situ RT-PCR (note the s
funiform cytoplasmic staining within the indicated cell).
The frequency of CD34(+) cells detected by this method
corresponds to an estimate of w1 CD34(+) cells per T
D35,000–50,000 total LN cells. This is in agreement with
the predicted frequency from our flow cytometry data I
tthat shows the cell to represent <0.05% of all events
without CD34(+) enrichment when using a live forward H
lscatter/side scatter gate (not shown). To our knowl-
edge, this represents the first identification of CD34(+) 5
cHPCs in human LN. Collectively, these results support
the notion that among all PB CD34(+) HPCs, it is the wD34dimCD45RA(+)β7bright subset that exclusively con-
ains the CD56bright NK precursor and selectively re-
ides in LN. Formal proof that this cell actually traffics
rom PB to LN will await further study.
Cell Activation Promotes CD56bright NK
ifferentiation In Vitro
mmunohistochemistry (IHC) staining on serial LN sec-
ions with an anti-CD3 mAb revealed that the CD34(+)
PCs we observed by in situ RT-PCR (Figure 5C) were
ocated within T cell-rich regions of LN sections (Figure
D), where we previously reported that CD56bright NK
ells also reside (Fehniger et al., 2003). To recapitulate
hat might occur in vivo during T cell activation, LN
A CD34(+) NK Precursor in Human Lymph Nodes
301Figure 6. T Cell Activation Supports CD56bright NK Cell Differentia-
tion from CD34(+) HPCs In Vitro
PB CD34brightCD45RA(+)β7dim/neg and CD34dimCD45RA(+)β7bright
subsets (n = 6) or total LN CD34(+) HPCs (>95% CD34dim
CD45RA(+)β7bright) (n = 3) were cultured for 7 days in exogenous
IL-2 or IL-15 (left column) or cocultured for 7 days with autologous
PB or LN CD3(+) T cells activated via CD3/CD28 stimulation (right
column). The CD3(−)CD14(−)CD56bright NK cells derived from these
cultures are seen in the upper left quadrant of each histogram. In
data not shown, a culture of sorted LN CD3(+) T cells stimulated
with anti-CD3/CD28 beads did not produce any CD56bright NK cells
without coculture of the CD34(+) HPCs.CD34(+) HPCs were cocultured with autologous LN
CD3(+) T cells in the presence of CD3/CD28 stimula-
tion. As shown in Figure 6, we observed CD3(−)CD14(−)
CD56bright NK cell development after only 7 days under
these conditions, along with a >10-fold increase in acti-
vated T cell numbers (not shown). We similarly cultured
purified PB CD34brightCD45RA(+)β7dim/neg and CD34dim
CD45RA(+)β7bright subsets with autologous PB CD3(+) T
cells and observed that, similar to the results obtained
by a 7-day culture in exogenous IL-2 or IL-15, only
CD34dimCD45RA(+)β7bright cells gave rise to NK cells in
the presence of CD3/CD28-stimulated T cells (Figure
6). The addition of an anti-IL-2 mAb to these cocultures
resulted in variable (average 25%, n = 9) reduction in
CD56bright NK cell development, likely due to the contri-
bution of other endogenous factors (e.g., IL-7, IL-15, IL-
21, KL) that might directly or indirectly contribute to this
process. Thus, activated LN T cells, in close proximity
to LN CD34dimCD45RA(+)β7bright HPCs, can induce hu-
man CD56bright NK cell differentiation without the addi-
tion of exogenous cytokines.
Discussion
NK cells are innate immune effectors that serve a
number of important functions in the body’s defense
against infection and malignant transformation. In oneinstance, the NK cell’s provision of IFN-γ to monocytes/
macrophages recently infected by obligate intracellular
pathogens results in a critical short-term containment
of infection while the more sustaining T cell response
can be mounted (Bendelac and Fearon, 1997). In other
instances, donor NK cell KIR mismatch with host MHC
class I expression on acute myeloid leukemia blasts
appears to be critical for predicting a favorable re-
sponse following haplo-identical bone marrow trans-
plantation (Ruggeri et al., 2002). Thus, both cytokine
production and cytolytic activity are important NK cell
properties in mediating effective host defense against
disease. In humans, these two NK functions can be
broadly assigned to two NK subsets. CD56bright NK
cells have few cytolytic granules and low-absent KIR
expression but produce abundant cytokines and che-
mokines when activated by monokines. CD56dim NK
cells do not produce appreciable amounts of cytokines
yet have abundant expression of KIR and perforin that
readily promote their potent cytolytic functions (Cooper
et al., 2001). Greater than 90% of NK cells in LN are
CD56bright, while w90% of NK cells in PB are CD56dim
(Fehniger et al., 2003).
While human NK cells originate from CD34(+) HPCs,
the site(s) of their differentiation and the developmental
relationship between CD56bright and CD56dim NK sub-
sets are currently unresolved (Colucci et al., 2003). To
date, no one CD34(+) subset has been shown to con-
tain all human NK precursors when differentiated to
CD56(+) NK in the presence of IL-2 or IL-15. We pre-
viously noted that the CD56bright NK cell has unique
constitutive expression of the heterotrimeric HA IL-
2Rαβγ among lymphocytes in resting blood (Caligiuri et
al., 1990) and hypothesized that its CD34(+) precursor
might also express this receptor and differentiate into
a CD56bright NK cell when the HA IL-2R was saturated.
In this report, we used this functional assay to initially
identify a novel CD34(+) subset of HPCs, subse-
quently characterized as CD34dimCD45RA(+)β7bright,
which, when cultured in IL-15 or IL-2, appears to con-
tain the NK precursor population in its entirety. The
CD34dimCD45RA(+)β7bright NK precursor cell coexpresses
other surface receptors and CAMs that facilitate traf-
ficking to LN (von Andrian and Mempel, 2003), and
we discovered that, among CD34(+) HPCs, the
CD34dimCD45RA(+)β7bright population is uniquely en-
riched within human LN. In addition to its NK develop-
ment in the presence of IL-2 or IL-15, we demonstrate
that endogenous T cell-derived cytokines can also
drive the CD34dimCD45RA(+)β7bright HPCs toward NK
cell differentiation. We therefore propose that this
unique subset of CD34(+) HPCs is produced in the BM
and traffics through the blood to finally reside in LN,
where it differentiates into a CD56bright NK cell under
the influence of endogenous cytokines.
Despite the results presented here, such a model
challenges the current conception of NK development
in vivo. First of all, while it is well established that the
human thymus contains NK precursors (Lanier et al.,
1992; Spits et al., 1998), it is generally accepted that, in
adults, NK development primarily occurs in the BM, as
its ablation results in the loss of lytic NK cells that can
be restored by BM transplantation (Colucci et al., 2003;
Hackett et al., 1985). However, this does not preclude
Immunity
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fic to the periphery for final maturation. For instance, i
adult human PB contains immature CD34(−)NKR- d
P1A(+)CD16(−)CD56(−) NK cells that mature in the pres- t
ence of IL-2 and IL-12 (Bennett et al., 1996). Further, a
Ferlazzo et al. (2004) recently suggested that late t
events in human CD56bright NK maturation likely occur
in peripheral lymphoid tissue, as the resident CD56bright I
NK cells in LN and tonsils can be induced with low- C
dose IL-2 to adopt functional and phenotypic qualities N
of PB NK. Our new finding that human CD34dim m
CD45RA(+)β7bright HPCs reside within LN and our previ- r
ous finding that their CD56bright NK progeny are highly e
enriched in LN (Fehniger et al., 2003) strongly implicate l
the LN as a site of early human NK cell differentiation. m
In adult mice, NK development is similarly thought to B
occur in the BM, yet it is noteworthy that selective NK q
deficiencies are found in mice lacking LN, while T or B F
cells are not deficient (Colucci et al., 2003). During d
mouse embryonic development, integrin α4β7(+) fetal M
lymphoid tissue-inducer (LTi) cells traffic to developing K
LN and Peyer’s patches (PP) and induce formation of C
these tissues (Mebius, 2003). Id2−/− mice lack fetal LTi i
cells and therefore fail to develop peripheral LN and PP o
(Yokota et al., 1999). Similarly, the absence of mem- c
brane lymphotoxin (LT)β expression on LTi cells also m
results in failure of these tissues to develop (Mebius, p
2003). As fetal LTi cells have the potential to differenti- m
ate into mature NK cells (Mebius et al., 1997), it is note-
worthy that both Id2−/− and LTβ−/− mice lack mature NK h
cells (Alimzhanov et al., 1997; Yokota et al., 1999). In N
light of these reports, it is interesting to speculate that a
human CD34dimCD45RA(+)β7bright HPCs may represent C
a similar cell population in man, and, if so, potentially g
regulate or maintain the generation of human second- C
ary lymphoid organs in vivo. w
Our ex vivo studies show that soluble IL-15, like IL-2, [
specifically acts on the CD34dimCD45RA(+)β7bright 2
HPCs to drive CD56bright NK cell differentiation. Further, t
cultures with other cytokines, such as KL, FL, IL-7, and T
the AFT024 fetal liver stromal cell line also indicate that v
either IL-2 or IL-15 are required for NK cell differentia- t
tion. Thus, in vivo, these two cytokines can likely both p
induce NK cell differentiation from the LN CD34dim
CD45RA(+)β7bright precursor, but their expression on dif- β
ferent immune cells and their differential expression
rduring immune quiescence and activation may dictate
mhow and when each contributes to this process.
CWhile the LN CD34dimCD45RA(+)β7bright HPCs consti- vtutively express the HA IL-2Rαβγ that selectively binds
CIL-2, the highly restricted availability of IL-2 strongly
asuggests that it alone cannot be responsible for
CD56bright NK cell development in the absence of T cell
E
activation. We propose that in the absence of antigen-
specific immune activation, CD56bright NK cell differen- P
tiation is regulated by cytokines known to be constitu- A
tively expressed by stroma and antigen-presenting I
pcells (e.g., FL, KL, and the requisite IL-15). Then, during
wprocesses that activate resident T cells in LN, endoge-
inously produced IL-2, along with other cytokines, might
f
contribute to drive CD56bright NK cell differentiation e
from LN CD34dimCD45RA(+)β7bright HPCs. These cyto- o
kines also promote autocrine LN T cell activation and m
pparacrine LN CD56bright NK cell activation (Fehniger etl., 2003). In this way, NK stores that were depleted dur-
ng the early phase of infection could be replenished
uring the late, antigen-specific phase of infection. Fu-
ure studies with in vivo models will be important to
ddress the hypothesis that adaptive immune activa-
ion can drive NK development.
In any of these scenarios, we would propose that
L-2 is not required for the survival of either the
D34dimCD45RA(+)β7bright HPC subset or the CD56bright
K cell, because of IL-2's restricted expression (Wald-
ann et al., 1998). We believe that the tyrosine kinase
eceptors, flt3 and c-kit, which we observed are also
xpressed on CD34dimCD45RA(+)β7bright precursors,
ikely mediate the survival signal(s) for this subset and
ay be involved in its development, as incubation of
M CD34(+) HPCs in either FL or KL increases the fre-
uency of NK cell precursors (Yu et al., 1998). Indeed,
L is produced in the BM, while KL is normally abun-
ant in both BM and human serum (Colucci et al., 2003;
rozek et al., 1996; Wodnar-Filipowicz, 2003). Further,
L binding and signaling through c-kit expressed on
D56bright NK cells mediates BCL-2-dependent survival
n serum-free medium (Carson et al., 1994). In addition,
ther cytokines signaling through the common IL-2Rγ
hain (Barao et al., 2003; Sivori et al., 2003) as well as
embrane bound LTβ (Iizuka et al., 1999) also likely
lay important roles in the generation, survival, and/or
aturation of CD34dimCD45RA(+)β7bright HPCs.
The insights gained from our study do not appear to
elp resolve the issue of human CD56bright and CD56dim
K subset development. CD56bright NK cells may have
pathway of development that is distinct from the
D56dim NK cell that lacks a functional HA IL-2R (Cali-
iuri et al., 1990). In our short-term cultures of the
D34dimCD45RA(+)β7bright precursor with IL-2 or IL-15,
e never observed the development of bona fide
CD16(+)KIR(+)c-kit(−)] CD56dim NK cells (Cooper et al.,
001), yet we currently have no data to suggest that
he CD56dim NK cell is derived from a separate HPC.
herefore, an alternative hypothesis is that a de-
eloping NK cell may first proceed from CD56bright to
he CD56dim NK cell, but again, data supporting this
athway are lacking (Colucci et al., 2003).
In summary, we identify a novel CD34dimCD45RA(+)
7
bright NK precursor cell that is uniquely enriched to
eside within the parafollicular T cell-rich region of hu-
an LN. We demonstrate that incubation of the
D34dimCD45RA(+)β7bright NK precursor cell with acti-
ated LN T cells can induce differentiation into a
D56bright NK cell. These data implicate the human LN
s a site for CD56bright NK cell development.
xperimental Procedures
urification of CD34(+) HPCs from Human Tissue
ll protocols were approved by The Ohio State University (OSU)
nstitutional Review Board. Fresh human BM was donated or
urchased from AllCells, LLC (Berkeley, CA) and was received
ithin 24 hr of harvest. PB leukopaks were obtained from the Amer-
can Red Cross. BM or PB mononuclear cells were enriched by a
icoll centrifugation step and then total CD34(+) cells were either
nriched over one magnetic column or purified (>97%, Figure S2)
ver two magnetic columns by using the Miltenyi CD34(+) enrich-
ent kit (Miltenyi Biotec, Auburn, CA). For sorting experiments and
henotypic analyses, total PB was treated with a rosette cocktail
A CD34(+) NK Precursor in Human Lymph Nodes
303against CD3, CD4, CD19, CD36, and glycophorin A (StemCell Tech-
nologies, Vancouver, BC, Canada) to deplete cells expressing these
markers during the ficoll centrifugation step. Human LN were re-
trieved fresh from surgically discarded tissue from non-cancer pa-
tients by the OSU Tissue Procurement Resource and from the Na-
tional Disease Research Interchange. LN single-cell suspensions
were prepared as described (Fehniger et al., 2003), and total
CD34(+) cells were enriched as described above. LN CD34(+) HPCs
were either stained for flow cytometric analyses or sorted to purity
for cell culture (Figure S2).
Flow Cytometry and Cell Sorting
All conjugated and unconjugated experimental and isotype control
mAbs used in this report were purchased from BD Biosciences,
except CD16, CD56, CD122 (IL-2Rβ), CD158a, CD158b, NKp30,
NKp44, NKp46 (Coulter, Miami FL), NKG2D (R&D Systems, Minne-
apolis, MN), and AC133 (Miltenyi Biotec, Auburn, CA). Nonspecific
binding was minimized by preincubation with whole mouse IgG (di-
rect primary staining) or whole goat IgG (indirect staining) (Sigma,
St. Louis, MO). Cells were assessed on a FACSCalibur analyzer and
analyzed with CellQuest (BD Biosciences) or WinMDI (J. Trotter,
Scripts Institute, La Jolla, CA) software. For culture experiments of
purified CD34(+) subsets, cells were sorted on a FACSVantage cell
sorter (BD Biosciences), and then sort purities were verified on a
FACSCalibur.
NK Cell Development Cultures
IL-2 was provided by Hoffman LaRoche (Nutley, NJ) and was used
at the indicated concentrations. FL and IL-15 were provided by
Amgen (Thousand Oaks, CA), and KL and IL-7 were from R&D Sys-
tems. Unless otherwise indicated, human NK development cultures
were initiated with 2 × 104 CD34(+) HPCs in 200 l complete me-
dium consisting of 1640 RPMI with GlutaMAX, 10% heat-inacti-
vated human AB serum (ICN Biomedicals, Irvine, CA), antibiotics,
10 mM HEPES, 100 M nonessential amino acids, 1 mM Na pyru-
vate (all from Invitrogen), and 50 M 2-βME (Sigma) plus exoge-
nous cytokines. Half of the culture medium was replaced every
3–4 days. At the time of final harvest, total cells/well were deter-
mined on a hemacytometer by using trypan blue dye exclusion.
The absolute numbers of mature CD56bright NK cells/well were cal-
culated by multiplying the average numbers of total viable cells
from triplicate wells by the average percent of CD3(−)CD14(−)
CD56bright NK cells determined by FACS analyses. For CD34(+)
HPC/T cell coculture experiments, 0.5–2 × 103 PB CD34(+) HPC
subsets or total LN CD34(+) HPCs were incubated with 2.5 × 103
autologous PB or LN CD3(+) T cells (purified via FacsVantage sort-
ing, Figure S2) stimulated with 5 × 103 anti-CD3/CD28 beads (Dynal
Biotech, Brown Deer, WI) in the presence or absence of 10 g/ml
anti-IL-2 or control Ab (R&D Systems). After 7 days of culture, cells
were harvested, counted for viability, and stained for flow cyto-
metry.
Functional Analyses of In Vitro-Derived NK Cells
Purified CD34(+) cells were cultured as described above for 2–4
weeks. To assess IFN-γ production by intracellular flow cytometry,
cultured cells were pooled and then resuspended at 106 cells/ml in
complete medium plus 10 ng/ml IL-12 (Genetics Institute, Cam-
bridge, MA) and 100 ng/ml IL-18 (BASF, Worcester, MA) for over-
night culture at 37°C. Golgi-plug (BD Biosciences) was added for a
4 hr incubation, and cells were next stained for surface CD3, CD14,
and CD56 and then permeabilized with the Cytofix/Cytoperm rea-
gent (BD Biosciences). Cells were stained with either anti-IFN-γ-
FITC mAb or isotype control-FITC mAb, washed, and then analyzed
by FACS. Alternatively, cultured cells were stimulated with recom-
binant monokines or 5 × 103 K562 target cells for 72 hr, and then
supernatants were analyzed by ELISA for cytokine production by
using Quantikine kits from R&D Systems. CD34(+)-derived
CD56bright NK cells were tested for their ability to lyse K562 target
cells in a standard chromium-release assay as described (Mrozek
et al., 1996; Yu et al., 1998).
Immunohistochemistry and In Situ RT-PCR
The protocols we used have been previously described (Fehniger
et al., 2003; Nuovo et al., 1999). Briefly, optimal protease digestionsof LN sections were followed by overnight incubation in RNase-
free DNase (10 U per sample, Boehringer Mannheim, Indianapolis,
IN) and one-step RT-PCR by using the rTth system and digoxigenin
dUTP (Nuovo et al., 1999). The primer sequences for CD34 mRNA
detection were: forward, 5#-accctgtgtctcaacatggca-3#; reverse, 5#-
tctctgatgcctgaacat-3#. Additional controls included pretreatment
with RNase digestion as well as RT-PCR with irrelevant primers
(HPV p16-specific primers) that have been described (Nuovo et al.,
1999). IHC with an anti-human CD3 mAb (Zymed Laboratories, Inc.,
San Francisco, CA) was performed as described (Fehniger et al.,
2003).
Statistical Analyses
The paired data were analyzed by using an exact Wilcoxon Signed
Rank test, and the unpaired data were analyzed by using an exact
Wilcoxon Rank Sum test. S-Plus version 6.0 and SAS version 8.02
were used for the analyses.
Supplemental Data
Supplemental Data including phenotypic analysis of PB CD56bright
NK cells, sample purities of sorting experiments, cell proliferation
data of purified CD34dimCD45RA(+)β7bright PB NK precursors, and
cytokine production data from CD34(+)-derived NK cells are avail-
able at http://www.immunity.com/cgi/content/full/22/3/295/DC1/.
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